Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Withdrawn 1Recruiting 1

Sponsor Class

INDUSTRY 2OTHER 1NIH 1

Study Type

Interventional 2

Sponsor

Cancer Type

Sarcoma 2Thoracic 1Gastrointestinal 1Dermatologic 1Breast 1

Conditions

Carcinoma, Non-Small-Cell Lung 302Parkinson Disease 4, Autosomal Dominant Lewy Body 180Melanoma 166Neoplasms 133Squamous Cell Carcinoma of Head and Neck 126Neoplasm Metastasis 98Colorectal Neoplasms 96Carcinoma, Renal Cell 80Triple Negative Breast Neoplasms 75Head and Neck Neoplasms 72Stomach Neoplasms 70Lung Neoplasms 68Breast Neoplasms 60Ovarian Neoplasms 56Carcinoma, Transitional Cell 51Uterine Cervical Neoplasms 44Endometrial Neoplasms 44Pancreatic Neoplasms 43Urinary Bladder Neoplasms 40Esophageal Neoplasms 40Carcinoma, Hepatocellular 37Small Cell Lung Carcinoma 30Cholangiocarcinoma 24Prostatic Neoplasms 22Carcinoma 22Lymphoma 20Carcinoma, Squamous Cell 20Recurrence 17Sarcoma 16Esophageal Squamous Cell Carcinoma 16

Interventions

Cyclophosphamide 6tazemetostat 5fludarabine 4pembrolizumab 2soblidotin 1reolysin 1pazopanib 1drozitumab 1cixutumumab 1atezolizumab 1anlotinib 1Tablets 1Rosuvastatin Calcium 1Rifampin 1Ramucirumab 1Radiation 1Quality of Life 1Patient Reported Outcome Measures 1Molecular Diagnostic Techniques 1Midazolam 1Itraconazole 1Injections 1Immunotherapy, Adoptive 1Immunotherapy 1Imatinib Mesylate 1Ifosfamide 1Gemcitabine 1Drug Therapy 1Doxorubicin 1Docetaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
INDUSTRY × Sarcoma, Synovial × pembrolizumab × Clear all
NCT05492682 2026-05-12

START: Safety and Anti-Tumor Activity of PeptiCRAd-1 in Treatment of Cancer

Valo Therapeutics Oy

Phase 1 Recruiting
15 enrolled
BreastDermatologicGastrointestinalSarcomaThoracic

Carcinoma, Non-Small-Cell Lung, Melanoma, Sarcoma, Osteosarcoma, Sarcoma, Synovial, Colorectal Neoplasms, Liposarcoma, Myxoid, Triple Negative Breast Neoplasms

NCT03697824 2019-10-29

Clinical Trial of Safety, Tolerability and Antitumor Activity of Genetically Engineered T Cells in Combination With Anti-Cancer Agents in Relapsed and Refractory Synovial Sarcoma Expressing New York Esophageal Antigen-1 (NY-ESO-1) and/or LAGE-1a

GlaxoSmithKline

Phase 2 Withdrawn
Sarcoma

Neoplasms, Sarcoma, Synovial

Data powered by HemOnc (CC BY 4.0) Colophon âš¡